{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-066376","form_type":"8-K","ticker":"RAPP","cik":"0002012593","company_name":"Rapport Therapeutics, Inc.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.682091+00:00","generated_at":"2026-05-22T05:48:56.516932+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Rapport Therapeutics Q1 net loss $24.1M; RAP-219 epilepsy trial on track for Q3 2025 data","bullets":["Net loss $24.1M in Q1 2025 vs $22.7M prior year; R&D expenses rose to $19.6M from $12.5M.","Cash & short-term investments $285.4M at Mar 31, 2025 (down from $305.3M Dec 31, 2024); runway through end of 2026.","RAP-219 Phase 2a refractory focal epilepsy topline results expected Q3 2025.","RAP-219 Phase 2a bipolar mania trial to start Q3 2025; topline data expected H1 2027.","Dr. Jeffrey Sevigny appointed CMO; Investor & Analyst Day scheduled June 2, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-066376","json":"https://secwatch.observer/filing/0000950170-25-066376.json","markdown":"https://secwatch.observer/filing/0000950170-25-066376.md","text":"https://secwatch.observer/filing/0000950170-25-066376.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2012593/000095017025066376/0000950170-25-066376-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2012593/000095017025066376/rapp-20250508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T05:48:56.516932+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}